Statins are among the most frequently prescribed drugs in Germany. Their benefits in lowering cardiovascular risk are beyond dispute. Nevertheless, many patients complain of side effects from statin therapy, including statin-associated muscle symptoms (SAMS) in particular. Despite their relative frequency, it is difficult to objectively diagnose them, as the time until appearance of first symptoms, the nature of the complaints and the severity of muscle problems vary widely. This narrative review summarizes the causes of SAMS as well as new possibilities regarding their diagnosis and therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00108-021-01059-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease.
J Intern Med
December 2024
Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Article Synopsis
- High-intensity statin therapy is effective in reducing mortality and cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), but elderly patients often tolerate moderate-intensity statins better due to intolerance risks.
- A study compared the incidence of statin-associated muscle symptoms (SAMS) and low-density lipoprotein cholesterol (LDL-C) levels in elderly ASCVD patients on either high-intensity statins or moderate-intensity statins combined with ezetimibe.
- Results showed that combination therapy significantly reduced SAMS (0.7% vs 5.7%) while achieving comparable LDL-C target levels (75.4% vs 68.7%), indicating that moderate-intensity therapy with ezetim
A Rare Case of Statin-Induced Rhabdomyolysis With Severe Acute Kidney Injury After a Decade of Therapy.
Cureus
November 2024
Emergency Medicine, Barking, Harvering and Redbridge Foundation Trust, London, GBR.
Cardiovascular diseases are a major global health concern, with statin therapy playing a significant role in primary and secondary prevention. Statin-associated muscle symptoms typically occur early in treatment, but severe rhabdomyolysis is a rare complication. We present an unprecedented case of a patient who developed severe rhabdomyolysis with acute kidney injury after 10 years of uninterrupted statin therapy.
View Article and Find Full Text PDFStatin-Associated Muscle Symptoms: Identification and Recommendations for Management.
Curr Atheroscler Rep
November 2024
Emory Department of Medicine, Lipid Clinic and Cardiovascular Risk Reduction Program, Emory University, Atlanta, GA, USA.
Article Synopsis
- Statins are the primary medication for lowering bad cholesterol (LDL), but some patients experience muscle-related side effects known as statin-associated muscle symptoms (SAMS).
- Recent guidelines from organizations like the National Lipid Association provide strategies for doctors to identify and manage patients with SAMS, as this is the most common reason for statin intolerance.
- Many patients can still tolerate some statin therapy, and when combined with non-statin medications, an effective treatment plan can be created through open discussions between clinicians and patients to lower the risk of heart disease.
Statin-associated muscle symptoms: Not simply a genetic predisposition.
Atherosclerosis
January 2025
Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Italy; Centro di Ricerca Coordinata sulle Interazioni Farmacologiche, Milan, Italy.
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.
BMJ Open
November 2024
Clinical Pharmacology Department, Hospital Universitario La Paz, Madrid, Spain
Introduction: Genetic variations impact drug response, driving the need for personalised medicine through pre-emptive pharmacogenetic testing. However, the adoption of pre-emptive pharmacogenetic testing for commonly prescribed drugs, such as statins, outside of tertiary hospitals is limited due to a lack of pharmacoeconomic evidence to support widespread implementation by healthcare policy-makers. The Spanish Consortium for the Implementation of Pharmacogenetics (iPHARMGx Consortium) addresses this by developing a clinical trial master protocol that will govern multiple nested adaptive clinical trials that compare genotype-guided treatments to standard care in specific drug-gene-population triads, asses their cost-efficacy and identify novel biomarkers through advanced sequencing techniques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!